Outlook Therapeutics (OTLK) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Outlook Therapeutics (OTLK) has outperformed Veraxa Biotech (VRXA) over the past year, losing 51.3% versus a loss of 88.0%. Veraxa Biotech is the larger company by market cap ($178.2 million vs $145.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | VRXA |
|---|---|---|
| Share price | $0.5989 | $1.26 |
| Market cap | $145.80M | $178.17M |
| 1-day change | +6.19% | +15.60% |
| YTD return | -62.09% | -88.19% |
| 1-year return | -51.31% | -87.97% |
| 5-year return | -98.58% | — |
| EPS (TTM) | $-0.74 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $27.36 |
| 52-week low | $0.161 | $1.04 |
| Distance from 52-week high | -76.40% | -95.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +739.87% | — |
| Average volume | 13.43M | 263.43K |
| Shares outstanding | 243.45M | 141.41M |
| Employees | 17 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OTLK has outperformed VRXA by 36.7 percentage points over the past year.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Healthcare · Biotechnology · 17 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Healthcare · Biotechnology
OTLK vs VRXA FAQ
Which is bigger, Outlook Therapeutics or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $178.17M compared with $145.80M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, OTLK or VRXA?
OTLK returned -51.31% over the past 12 months, compared with -87.97% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Outlook Therapeutics and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.